Louisiana is currently home to 885 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Orleans, Baton Rouge, Shreveport and Metairie. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
NCT05507216
Recruiting
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhibitors, anti-integrin... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
07/25/2024
Locations: Tandem Clinical Research, LLC, Marrero, Louisiana
Conditions: Ulcerative Colitis
Register for Updates
Registry of Avance® Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction
NCT01526681
Recruiting
This study is a registry of general use of Avance Nerve Graft and is intended to evaluate the uses, response rates, and safety of Avance Nerve Graft in the real-life clinical setting. Optional addendums 1 and 2 included in the protocol are intended to establish comparative groups and focused subgroups within the registry.
Gender:
ALL
Ages:
All
Trial Updated:
07/25/2024
Locations: Sensation-NOW: Advanced Reconstructive Care, LLC, Metairie, Louisiana
Conditions: Peripheral Nerve Injuries
Register for Updates
ARrest RESpiraTory Failure From PNEUMONIA
NCT04193878
Recruiting
This research study seeks to establish the effectiveness of a combination of an inhaled corticosteroid and a beta agonist compared to placebo for the prevention of acute respiratory failure (ARF) in hospitalized patients with pneumonia and hypoxemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2024
Locations: Tulane University - Main & BUMC, New Orleans, Louisiana
Conditions: Pneumonia, Hypoxemia, Acute Respiratory Failure, COVID-19 Pneumonia
Register for Updates
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
NCT02735707
Recruiting
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19. REMAP-COVID is a sub-platform of REMAP-CAP th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2024
Locations: Tulane Medical Center, New Orleans, Louisiana
Conditions: Community-acquired Pneumonia, Influenza, COVID-19
Register for Updates
Study of ALTO-300 in MDD
NCT05922878
Recruiting
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/05/2024
Locations: Site 201, Marrero, Louisiana
Conditions: Major Depressive Disorder
Register for Updates
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
NCT05806515
Recruiting
This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping, or slowing the growth of tumor cells. Giving carboplatin before surgery may shrink tumors in patients with h... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/05/2024
Locations: LSU Healthcare Network / Metairie Multi-Specialty Clinic, Metairie, Louisiana
Conditions: Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Register for Updates
Evaluating Glial Acetate Metabolism as a Biomarker of Hypoglycemic Counterregulation
NCT04207619
Recruiting
Hypoglycemic complications are a major impediment to the maintenance of healthy glucose levels in persons with diabetes. The investigators recently completed a clinical pilot and feasibility study (GLIMPSE, NCT02690168), which identified a novel biomarker, glial acetate metabolism, that appears to predict the susceptibility to hypoglycemia. By providing an assay to predict hypoglycemic events and therefore diabetic complications, the development of this biomarker could significantly improve the... Read More
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
07/05/2024
Locations: Pennington Biomedical Research Center, Baton Rouge, Louisiana
Conditions: Diabetes, Hypoglycemia
Register for Updates
A Study of Vibegron in Pediatric Participants 2 Years to Less Than (<) 18 Years of Age With NDO and on CIC
NCT05491525
Recruiting
The purpose of this study is to evaluate the safety, efficacy, and PK of vibegron in pediatric participants with NDO who are regularly using CIC
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
07/02/2024
Locations: Childrens Hospital New Orleans, New Orleans, Louisiana
Conditions: Neurogenic Detrusor Overactivity
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Christus Saint Frances Cabrini Hospital, Alexandria, Louisiana
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.
NCT06482554
Recruiting
This study is looking to determine if Lumateperone improves motivation in patients with schizophrenia or schizoaffective disorders who show high levels of apathy as judged by AES-C-Apathy (Apathy Evaluation Scale - Clinician - Apathy) assessment and to examine a possible correlation between improvement in apathy scores and changes in elements of the PANSS (Positive and Negative Syndrome Scale) due to treatment with Lumateperone.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/26/2024
Locations: LSU Health Shreveport, Shreveport, Louisiana
Conditions: Apathy, Schizophrenia, Schizophrenia; Psychosis
Register for Updates
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
NCT03053193
Recruiting
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: Louisiana State University, Shreveport, Louisiana
Conditions: Breast Cancer
Register for Updates
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
NCT05230537
Recruiting
The purpose of this study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD) eyes to new incomplete retinal pigment epithelium and outer retinal atrophy (iRORA) or late AMD.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/24/2024
Locations: Retina Associates New Orleans ., New Orleans, Louisiana
Conditions: Age-Related Macular Degeneration
Register for Updates